Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets

Zaid, Abdel Naser; Malkieh, Numan; Kharoaf, Maher; Ghoush, Abeer Abu; Al-Ramahi, Rowa'

Abstract

Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets

Author(s): Zaid Abdel Naser, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'

Issue: Jul/Aug 2012 - Volume 16, Number 4

View All Articles in Issue

Page(s): 342-346

Download in electronic PDF format for $75

Abstract

The purpose of this study was to formulate a 25-mg atenolol capsule starting from a commercial 100-mg atenolol tablet, given the fact that this strength is not available in Palestine and also because 50-mg atenolol tablets failed the splitting uniformity test of the European Pharmacopoeia, and to evaluate the chemical stability and dissolution behavior of the obtained capsules so as to ensure a high-quality product. A high-performance liquid chromatographic system was used for the analysis and quantification of atenolol in the samples studied. Samples of atenolol for analysis were prepared as reported by the United States Pharmacopeia monograph. Disintegration and dissolution tests were performed according to the United States Pharmacopeia. The high-performance liquid chromatography assay indicated that the 25-mg atenolol capsules were stable for four months when stored at ambient temperature conditions. The disintegration time for all atenolol capsules was within the United States Pharmacopeia limits of 15 minutes. Atenolol release profile showed that approximately 90% of atenolol dissolved after 10 minutes. This study is important for patients who need to take one half of a 50-mg tablet, but for whom the splitting process doesn’t give equal halves, and also for modifying the dose for patients with renal or hepatic problems. Therefore, it is possible for the community pharmacist to crush atenolol 100-mg tablets and refill them in new capsules with each containing a precise amount of atenolol, calculated according to body surface area and kidney and liver functions without affecting the chemical stability of the active ingredient nor its dissolution profile and also have a cost effective dosage form.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2012 Pg. 342-346	Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets Author(s): Zaid Abdel Naser, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'
Jan/Feb 2015 Pg. 60	Atenolol 25-, 50-, or 100-mg Capsules Author(s): Allen Loyd V Jr
May/Jun 2018 Pg. 233	Atenolol 1 mg/mL or 5 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
May/Jun 2003 Pg. 233-239	Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Author(s): Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
Nov/Dec 1997 Pg. 437-439	Short-Term Stability of Atenolol in Oral Liquid Formulations Author(s): Patel Dipali, Doshi Dharmesh H, Desai Archana
Mar/Apr 2016 Pg. 167-174	Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions Author(s): Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MA
Jan/Feb 2001 Pg. 9-12	Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients Author(s): Schotik Debora
May/Jun 2020 Pg. 194-197	Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality Author(s): Hagan John C III, Everett Eric, Chamberlain Tyler
Nov/Dec 2012 Pg. 513-515	Stability of Propranolol Hydrochloride in SyrSpend SF Author(s): Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
Jul/Aug 2013 Pg. 333	Metoprolol Tartrate 1-mg/mL Injection Author(s): Allen Loyd V Jr
Jul/Aug 2021 Pg. 327	Nifedipine 4.mg/mL in SyrSpend SF pH4 Cherry Flavored Author(s): Allen Loyd V Jr
Sep/Oct 2022 Pg. 364-368	A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans Author(s): Riepl Mike
Sep/Oct 2015 Pg. 414-419	Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Author(s): Fortner Jeff, Salton Jason, Carlson Christie, Wheeler Rich, Cote Brianna, Rao Deepa
Sep/Oct 2005 Pg. 402-406	Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations Author(s): Sidhom Madiha B, Rivera Nadya, Almoazen Hassan, Taft David R, Kirschenbaum Harold L
May/Jun 2009 Pg. 250-253	Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A Comparison of Two Methods of Compounding Author(s): Garg Sanjay, Svirskis Darren, Al-Kabban Majid, Farhan Samer, Komeshi Mohammed, Lee Jacky, Liu Quincy, Naidoo Sacha, Kairuz Therese
Mar/Apr 2010 Pg. 108-111	Coenzyme Q10 Supplementation in the Treatment of Heart Disease Author(s): Bramwell Bethany L
May/Jun 2013 Pg. 233	Labetalol 50-mg Capsules Author(s): Allen Loyd V Jr
Jan/Feb 2016 Pg. 41-45	Formulation and Stability of Solutions Author(s): Akers Michael J
Jan/Feb 2017 Pg. 83-87	A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding Author(s): Rush Steven D, Vernak Charlene, Zhao Fang
Jul/Aug 2017 Pg. 334-338	Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt Author(s): Graves Richard, Phan Kelly V, Bostanian Levon A, Mandal Tarun K, Pramar Yashoda V